KidneyCure Ltd., an Israel-based biotechnology company, is developing novel and proprietary, regenerative cell therapies for the treatment of advanced Chronic Kidney Disease (CKD). This exceptional therapeutic approach is expected to significantly delay the need for dialysis and kidney transplantation and to give CKD patients the opportunity to live longer, better-quality and more productive lives.
CKD is reaching epidemic proportions worldwide. In the US alone, the overall prevalence of CKD is estimated at more than 30 million. Of these, more than 120,000 CKD patients develop end-stage renal disease (ESRD, or CKD stage 5) each year. Overall, it is estimated that 650,000 patients in the US and more than 3 million patients worldwide are affected by ESRD. Total annual Medicare spending on patients with CKD exceeds $64 billion, equaling 20% of the total Medicare annual budget. Furthermore, nearly 90% of US ESRD patients are put on dialysis, with an average annual cost of approximately $100,000 per patient. Despite the extensive resources committed to CKD treatment, the incidence of ESRD in the US, EU and other regions is rapidly increasing as the population ages.
KidneyCure’s 3-Dimensional Adult Nephroforms, 3DAN™-001, cellular-based therapy aims to compensate for renal cell depletion by administrating revived, autologous, renal epithelial cells. Upon administration, 3DAN™-001 therapy is expected to reduce inflammation and formation of renal fibrosis, to facilitate renal tubular function, and by doing so, to significantly improve kidney function.